Pluri Chairman Alejandro Weinstein’s Cumulative Investment Exceeds $17 Million, Ownership Surpasses 30%
Rhea-AI Summary
Pluri (Nasdaq, TASE: PLUR) reported that Chairman Alejandro Weinstein has invested more than $17 million in the company over the past year, including a $1.25 million advance investment in June 2026 under an Advance Subscription Agreement. According to Pluri, Weinstein now owns more than 30% of the company’s issued and outstanding shares.
Pluri links this growing stake to its shift from platform development toward commercial execution, with an emphasis on longevity and planned U.S. commercialization. The company reports strong inbound interest from multiple U.S. parties assessing potential product purchases and technology collaborations around reproducible cell production, tailored exosomes and other biological components.
Positive
- Chairman investment exceeds $17 million over past year, including $1.25 million in June 2026
- Ownership surpasses 30%, aligning Chairman Alejandro Weinstein’s stake with long-term company performance
- Advance Subscription Agreement used for $1.25 million June 2026 investment, signaling structured ongoing funding support
- Strong inbound U.S. interest in potential product purchases and technology collaborations, according to Pluri
- Clear strategic focus on longevity, U.S. commercialization and tailored biologics backed by board-level support
Negative
- None.
News Explained
The July 14 release adds scale to an already disclosed ownership position: Weinstein’s more-than-
Sources and calculations
- Pluri cumulative investment and ownership update (2026-07-14)
- Pluri third-quarter report (2026Q3)
- Offering gross vs quarterly operating cash outflow, in days of cash use $17,000,000 / ($4,512,000 / 90) = [object Object]
Market reaction after chairman investment and ownership update: PLUR +3.07% in the Jul 14 session
In the Jul 14 session, PLUR gained 3.07%, reflecting a moderate positive market reaction. Argus tracked a trough of -15.7% from its starting point during tracking. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility. Trading volume was above average at 1.6x the daily average, suggesting increased trading activity.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jun 02 | U.S. launch preparation | Neutral | -1.9% | Subsidiary Cellav completed U.S. listings enabling 2026 regenerative aesthetics launch. |
| Mar 26 | Insider private placement | Neutral | -3.3% | Chairman-affiliated entity invested $2.5M at 30% premium via private placement. |
| Feb 18 | China patent grant | Neutral | -1.1% | China patent granted for 3D immune cell expansion and activation technology. |
| Jan 22 | Program phase completion | Neutral | +9.3% | Completed first phase of Resbiomed program for placenta-derived biomaterials. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent Pluri headlines, including IP, commercial and financing updates, have often been followed by modest single-digit price moves, with one notable positive reaction on a regenerative biomaterials milestone.
Key Terms
advance subscription agreement financial
exosomes medical
glp-1-based therapies medical
3d cell-expansion platform technical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Through a series of investments over the past year, including an additional investment made in June 2026, Weinstein has built an ownership position of more than
HAIFA, Israel, July 14, 2026 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq, TASE: PLUR), a biotechnology company leveraging a proprietary cell-based platform across multiple commercial verticals, today provided an update on the cumulative investment and ownership position of its Chairman, Mr. Alejandro Weinstein. Over the past year, Mr. Weinstein has invested more than
Mr. Weinstein is a global investor and entrepreneur with more than two decades of experience across pharmaceuticals, biotechnology and wellness. As previously reported by Pluri, he has participated in more than 20 M&A transactions and over
His interest in the company is based on Pluri’s ability to translate its scientific and technological capabilities into commercial opportunities. As Chairman, Mr. Weinstein has supported a strategic focus on commercialization, disciplined resource allocation and execution across the Company’s platform and business verticals. Pluri is now advancing commercial initiatives in the United States and other markets, reflecting its broader transition from platform development toward commercial operations.
“My commitment to Pluri is reflected in the position I have built over the past year and is based on a clear belief in the Company’s platform, people and assets,” said Alejandro Weinstein, Chairman of the Board of Pluri. “I am convinced that Pluri’s platform holds significant and still largely untapped value, particularly as the Company expands its focus in the rapidly growing longevity sector. The impact of peptide-based medicines, including GLP-1-based therapies developed by Eli Lilly and Novo Nordisk, highlights the strategic value of precision biologics. Pluri can already produce tailored exosomes with distinct biological cargo profiles. We believe this capability could support a future generation of biologic products and attract interest from strategic investors and pharmaceutical companies. Together with reproducible cell production at scale, this creates a differentiated foundation for commercialization. Pluri’s shift toward commercial execution in the U.S. market, with a focus on longevity, tailored biologics and regenerative solutions, is exactly the direction I believe in. I am committed to seeing this strategy through and helping unlock the full potential of the Company for its shareholders.”
“Alejandro’s cumulative investment is a strong expression of confidence in Pluri’s strategy and long-term potential,” said Yaky Yanay, President and Chief Executive Officer of Pluri. “As Chairman and one of our largest shareholders, Alejandro has been actively involved in sharpening our commercial focus and supporting our transition toward market execution. We are seeing strong inbound interest from multiple U.S. parties interested in potential product purchases and technology collaborations built around our capabilities in reproducible cell production, tailored exosomes and unique biological components. His additional investment made in June further reinforces that long-term commitment as we move from platform development toward commercial execution.”
About Pluri
Pluri™ is pushing the boundaries of science and engineering to create cell-based products for commercial use and is pioneering a biotech revolution that promotes global well-being and sustainability. The Company’s technology platform, a patented and validated state-of-the-art 3D cell expansion system, advances novel cell-based solutions for a range of challenges, from medicine and climate change to food scarcity, animal cruelty and beyond. Pluri currently operates in the regenerative medicine, regenerative aesthetics, exosomes, longevity, foodtech and agtech fields and offers Contract Development and Manufacturing Organization (CDMO) services. To learn more, visit www.pluri-biotech.com or follow Pluri on LinkedIn and X.
Safe Harbor Statement
This press release contains express or implied forward-looking statements within the Private Securities Litigation Reform Act of 1995 and other U.S. federal securities laws. For example, Pluri is using forward-looking statements when it discusses its commercial expansion in the United States; opportunities in longevity, tailored biologics and exosomes; its ability to produce tailored exosomes with distinct biological cargo profiles; the potential of such exosomes to support future biologic products; expected interest from strategic investors, pharmaceutical companies and other partners; and Pluri’s strategy, long-term potential and unlocking potential for shareholders. These statements are based on management’s current expectations and are subject to risks and uncertainties, including the Company’s ability to execute its commercialization strategy, develop and manufacture tailored exosome products, secure orders and collaborations, satisfy regulatory requirements, protect intellectual property, obtain capital and compete successfully, as well as general market, economic and geopolitical conditions. References to Eli Lilly and Novo Nordisk are for market context only and do not imply any relationship or endorsement. Except as required by law, Pluri undertakes no obligation to update these statements. For a more detailed description of the risks and uncertainties affecting Pluri, reference is made to Pluri’s reports filed from time to time with the Securities and Exchange Commission.
Contact
investor.relations@pluri-biotech.com
